Forte Biosciences, Inc. (FBRX) News
Filter FBRX News Items
FBRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest FBRX News From Around the Web
Below are the latest news stories about FORTE BIOSCIENCES INC that investors may wish to consider to help them evaluate FBRX as an investment opportunity.
Forte Biosciences to Host R&D Day December 3, 2024DALLAS, November 25, 2024--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will host an R&D Day on December 3, 2024 at 4:30 p.m. ET. |
Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune IndicationsDALLAS, November 20, 2024--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced an oversubscribed $53 million equity financing to support the continuing clinical advancement of FB102. |
Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business UpdateDALLAS, November 14, 2024--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced third quarter 2024 results and provided a business update. |
Upcoming Stock Splits This Week (August 26 to August 30) – Stay InvestedThese are the upcoming stock splits for the week of August 26 to August 30, based on TipRanks’ Stock Splits Calendar. A stock split is a corporate action in which the company issues additional common shares to increase the number of outstanding shares. Accordingly, the stock price of the company’s shares decreases, which maintains the market capitalization before and after the split. In contrast, there are also reverse stock splits that reduce the number of outstanding shares (consolidate). In t |
Forte Biosciences, Inc. Announces Second Quarter 2024 Results and Provides Business UpdateDALLAS, August 14, 2024--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced second quarter 2024 results and provided a business update. |
Companies Like Forte Biosciences (NASDAQ:FBRX) Could Be Quite RiskyEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing RulesDALLAS, May 17, 2024--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. |
Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business UpdateDALLAS, May 13, 2024--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced first quarter 2024 results and provided a business update. |
Forte Biosciences, Inc. Announces 2023 Results and Provides Business UpdateDALLAS, March 18, 2024--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its 2023 results and provided a business update. |